Remote monitoring and digital health tools in CVD management
- PMID: 33824486
- PMCID: PMC8023506
- DOI: 10.1038/s41569-021-00548-x
Remote monitoring and digital health tools in CVD management
Abstract
The COVID-19 pandemic has accelerated the adoption and acceptance of remote monitoring and other digital approaches to cardiovascular disease management across the world. We argue that considerable additional effort is required to ensure appropriate multi-stakeholder involvement in the development, evaluation and best use of an ever-increasing number of digital technologies.
Conflict of interest statement
M.R.C. is chair of the Digital Health Committee of the ESC. He has received research funds and consultancy fees from Abbott, Boston Scientific and Medtronic. He provides consultancy advice to AstraZeneca as Chief Physician–Scientist (heart failure). C.S.P.L. has received research support from AstraZeneca, Bayer, Boston Scientific and Roche Diagnostics; has served as consultant or on the Advisory Board, Steering Committee or Executive Committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, Janssen Research & Development, Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group, Roche Diagnostics, Sanofi, Us2.ai and WebMD Global; and serves as co-founder and non-executive director of Us2.ai.
References
-
- Mueller, B. Telemedicine arrives in the U.K.: ‘10 years of change in one week’. The New York Timeshttps://www.nytimes.com/2020/04/04/world/europe/telemedicine-uk-coronavi... (2020).
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
